Zodasiran

RNA / oligonucleotide

Also known as VSA003

Phase 3underway

Evidence outlook · registrational

Homozygous Familial Hypercholesterolemia: registrational readout pending

No completed mid-stage readout is on record. Registrational readout expected around 2027-08-20.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (3)
Homozygous Familial Hypercholesterolemia
NCT07473843 · Arrowhead Pharmaceuticals
2026-10 – 2028-08 · Homozygous Familial Hypercholesterolemia
What this study did
Phase 2 (2)
Homozygous Familial Hypercholesterolemia
NCT05217667 · Arrowhead Pharmaceuticals
2022-04-22 – 2025-11-13 · Homozygous Familial Hypercholesterolemia
What this study did
Other / comorbidity
NCT04832971 · Arrowhead Pharmaceuticals
2021-06-28 – 2024-09-25 · Mixed Dyslipidemia
What this study did
Phase 1 (2)
Other / comorbidity
NCT05851066 · Visirna Therapeutics HK Limited
2023-06-01 – 2024-05-07 · Dyslipidemias, Familial Hypercholesterolemia, Hypertriglyceridemia
What this study did
NCT03747224 · Arrowhead Pharmaceuticals
2019-01-07 – 2021-05-17 · Dyslipidemias, Familial Hypercholesterolemia, Hypertriglyceridemia
What this study did

Competitive landscape

This drug's own stage for Homozygous Familial Hypercholesterolemia: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Zodasiran: this drugPhase 3RNA / oligonucleotideANGPTL3 gene mRNA (hepatic)not yet gradedNo reviewed efficacy summary in this indication
Alirocumab (Praluent)ApprovedMonoclonal antibodyPCSK9Partial signal
NCT03156621: Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 12 (Intent-to-Treat [ITT] Estimand) (Baseline to Week 12): Alirocumab 150 mg SC Q2W -26.9 Percentage of change (Standard Error 4.6) vs Placebo in DBTP 8.6 Percentage of change (Standard Error 6.3)
Evinacumab (Evkeeza)ApprovedMonoclonal antibodyANGPTL3Partial signal
NCT03399786: Percent Change in Calculated Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 24 (Intent-to-Treat [ITT] Estimand) (Week 24): Evinacumab 15 mg/kg IV Q4W -47.1% (Standard Error 4.6) vs Placebo IV Q4W 1.9% (Standard Error 6.5)
Evolocumab (Repatha)ApprovedMonoclonal antibodyPCSK9Reliable signal
NCT01588496: Part B: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12: Evolocumab -23.05% (Standard Error 3.78) vs Placebo 7.88% (Standard Error 5.26); LS mean treatment difference -30.93% (95% CI -43.86 to -18.00), p<0.001
Ezetimibe (Zetia)ApprovedSmall moleculeDietary Cholesterol Absorption Inhibitor, NPC1L1not yet gradedNo reviewed efficacy summary in this indication
Ezetimibe / Simvastatin (Vytorin)ApprovedSmall moleculeHMG-CoA reductase / NPC1L1not yet gradedNo reviewed efficacy summary in this indication
Inclisiran (Leqvio)ApprovedRNA / oligonucleotidePCSK9Partial signal
NCT04659863: Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1) (Baseline and Day 330): Part 1- Inclisiran -21.6% (Standard Deviation 13.36) vs Part 1 - Placebo 11.7% (Standard Deviation 30.52)
Lomitapide (Juxtapid)ApprovedSmall moleculeMTPWeak signal
NCT04681170: Efficacy Endpoint: Percent Change in Low-density Lipoprotein Cholesterol (LDL C) at Week 24 Compared to Baseline (Baseline through Week 24): Age 5-10 Years -56.529% (Standard Deviation 26.5401) | Age 11-17 Years -51.633% (Standard Deviation 25.5658)
NCT02173158: Percent Change in LDL-C (Baseline to Week 26): Lomitapide -42.2% (Standard Deviation 18.16)
RosuvastatinApprovedSmall moleculeHMG-CoA reductasenot yet gradedNo reviewed efficacy summary in this indication
SHR-1918Phase 3Monoclonal antibodyANGPTL3Partial signal
NCT06723652: LDL-C -58.8% vs +5.5% with placebo at week 12 (difference -64.2%), ESC 2026

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Zodasiran to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
August 2027 (1)
Phase 3Homozygous Familial HypercholesterolemiaActive not recruiting
Est. primary completion 2027-08-20 · NCT07037771 · CT.gov ↗
What to watch
2028 (1)
July 2028 (1)
Phase 3Homozygous Familial HypercholesterolemiaRecruiting
Est. primary completion 2028-07 · NCT07473843 · CT.gov ↗
What to watch

See the full readout calendar ↗